Logo-ajcmi
Submitted: 01 Aug 2016
Revision: 17 Sep 2016
Accepted: 02 Oct 2016
ePublished: 16 Oct 2016
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

Avicenna J Clin Microbiol Infect. 2016;3(4): 41142.
doi: 10.17795/ajcmi-41142
  Abstract View: 807
  PDF Download: 406

Research Article

Assessment of the Response to Treatment in Patients with the Hepatitis C Virus Infection: A Quantitative Study by Focusing on Virologic and Biochemical Responses

Peyman Eini 1, Mojgan Mamani 2*, Fatemeh Keshavarz 3, Abbas Moradi 4

1 Brucellosis Research Centre, Department of Infectious Diseases, Hamadan University of Medical Sciences, Hamadan, Iran
2 Department of Infectious Diseases, Hamadan University of Medical Sciences, Hamadan, Iran
3 General Practitioner, Hamadan University of Medical Sciences, Hamadan, Iran
4 Department of Community Medicine, Hamadan University of Medical Sciences, Hamadan, Iran
*Corresponding Author: Corresponding author: Mojgan Mamani, Brucellosis Research Centre, Sina Hospital, Mirzadeh-Eshghi Street, Hamadan 65168, Iran. Tel: +98-8138274192, Fax: +98-8138276010,, Email: mojganmamani@gmail.com

Abstract

Objectives: The main goal of the treatment of the hepatitis C virus (HCV) infection is reduction and elimination of viruses as well as achieving high sustained viral response (SVR). The present study aimed to assess response to treatment of HCV infection by focusing on virological and biochemical aspects.

Methods: This study was performed in Hamadan, Iran on HCV infected patients who were referred between 2009 and 2013. All participants were under the treatment with Pegylated Interferon (PEG-IFN) and Ribavirin (RBV). The duration of treatment varied based on the HCV genotype as 24 weeks for genotypes 2 and 3, and 48 weeks for other genotypes.

Results: Of the 186 patients with HCV infection, 52.8% had a genotype of 3a and 35.6% had a genotype of 1a/b. Three months after treatment, 75 patients were willing to do quantitative PCR and early virologic response was observed in 58 cases (78.4%). Also, 112 patients were assessed after completing the treatment (75 patients in 24 weeks and 37 patients in 48 weeks treatment protocol) and the end-of-treatment response (ETR) was 94.7% and 86.5% respectively. Amongst the 103 patients with ETR, 76 were followed up six months after treatment and the PCR was negative in 71 cases (SVR = 93.4). With the progress and completion of the treatment, improvement is observed in liver function tests.

Conclusions: Even with the introduction of new drugs and interferon free protocols in treatment of hepatitis C infection it seems that the IFN-based treatment is still used in low/middle income countries for treatment-naive patients with HCV genotype 3.


Copyright © 2016, Hamadan University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 808

Your browser does not support the canvas element.


PDF Download: 406

Your browser does not support the canvas element.